Pacira BioSciences Reports Q2 2026 Financial Results

What Happened
Pacira BioSciences, Inc. announced its financial results for the second quarter ended June 30, 2026 by issuing a press release on August 4, 2026. The company furnished the full press release as Exhibit 99.1 to its Form 8-K (Item 2.02: Results of Operations and Financial Condition). The Form 8-K was signed by Kristen Williams, Chief Administrative Officer and Secretary.

Key Details

• Event: Form 8-K filed to report quarterly results (Item 2.02).
• Press release date: August 4, 2026; covers quarter ended June 30, 2026 (Exhibit 99.1).
• Filing/Formalities: Press release furnished on Form 8-K; filing also includes Inline XBRL cover page (Exhibit 104).
• Signatory: Report signed by Kristen Williams, Chief Administrative Officer and Secretary.

Why It Matters
This filing officially notifies investors that Pacira has released its Q2 2026 quarterly results—key information for evaluating recent revenue, earnings, and operational performance. The 8-K itself furnishes the press release but does not restate the financial figures within the body of the Form; investors should review the attached press release (Exhibit 99.1) and the company’s quarterly SEC filings for the detailed revenue, EPS, and other metrics.